Just for the record. I have no concerns in regards to safety, and one would think that the process should be able to produce consistent product. The problem is efficacy. No one here has given any consideration to what one should expect a suitable control to show in terms of 2 year mortality rates. What is more important CYP have not informed the market either. The best they can do is show results of two trials that enrolled Rux refractory patients.
Moving on, CYP have well informed the market of its technology advantages, all good points but what about the disadvantages? Do you all think that there is no problems to be solved?
CYP Price at posting:
31.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)